We are live on ! Find out more
AZN icon

AstraZeneca

544 hedge funds and large institutions have $17.3B invested in AstraZeneca in 2018 Q3 according to their latest regulatory filings, with 65 funds opening new positions, 151 increasing their positions, 197 reducing their positions, and 47 closing their positions.

New
Increased
Maintained
Reduced
Closed

207% more call options, than puts

Call options by funds: $225M | Put options by funds: $73.5M

38% more first-time investments, than exits

New positions opened: 65 | Existing positions closed: 47

23% more capital invested

Capital invested by funds: $14B → $17.3B (+$3.3B)

3% more funds holding

Funds holding: 530544 (+14)

1.19% more ownership

Funds ownership: 16.09%17.28% (+1.2%)

23% less repeat investments, than reductions

Existing positions increased: 151 | Existing positions reduced: 197

40% less funds holding in top 10

Funds holding in top 10: 53 (-2)

Holders
544
Holders Change
+14
Holders Change %
+2.64%
% of All Funds
12.44%
Holding in Top 10
3
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-40%
% of All Funds
0.07%
New
65
Increased
151
Reduced
197
Closed
47
Calls
$225M
Puts
$73.5M
Net Calls
+$152M
Net Calls Change
+$45M
Name Holding Trade Value Shares
Change
Change in
Stake
UBS Group
26
UBS Group
Switzerland
$94.1M -$12.2M -160,780 -12%
Citadel Advisors
27
Citadel Advisors
Florida
$94.1M -$1.65M -21,848 -2%
Royal Bank of Canada
28
Royal Bank of Canada
Ontario, Canada
$88.1M -$7.33M -96,901 -8%
YCMGA
29
York Capital Management Global Advisors
New York
$84.8M -$13.3M -176,369 -14%
Canada Pension Plan Investment Board
30
Canada Pension Plan Investment Board
Ontario, Canada
$83.8M
Bank of Montreal
31
Bank of Montreal
Ontario, Canada
$74.5M +$36.7M +485,428 +107%
CIC
32
Crawford Investment Counsel
Georgia
$69M +$625K +8,262 +1%
CBT
33
Capital Bank & Trust
California
$68.6M +$1.38M +18,225 +2%
Invesco
34
Invesco
Georgia
$67.6M -$5.33M -70,468 -8%
CGT
35
Capital Guardian Trust
California
$65.5M +$4.04M +53,424 +7%
SCCM
36
Schafer Cullen Capital Management
New York
$61.3M -$102M -1,342,099 -63%
BCM
37
Becker Capital Management
Oregon
$58.3M -$1.78M -23,534 -3%
HJGA
38
Hardman Johnston Global Advisors
Connecticut
$52.9M +$4.02M +53,160 +9%
Russell Investments Group
39
Russell Investments Group
United Kingdom
$51.5M +$36.5M +483,231 +290%
AllianceBernstein
40
AllianceBernstein
Tennessee
$48.2M -$8.12M -107,338 -15%
Balyasny Asset Management
41
Balyasny Asset Management
Illinois
$45.2M +$2.8M +37,020 +7%
SEI Investments
42
SEI Investments
Pennsylvania
$44.6M -$7.28M -96,287 -15%
AAMU
43
Amundi Asset Management US
Massachusetts
$42.9M +$56.6K +748 +0.1%
TA
44
Teachers Advisors
New York
$41.3M +$4.28M +56,633 +12%
AG
45
Aperio Group
California
$39.9M +$1.65M +21,770 +5%
TD Asset Management
46
TD Asset Management
Ontario, Canada
$39.4M -$2.56M -33,825 -6%
TCIM
47
TIAA CREF Investment Management
New York
$32.4M +$12.4M +163,409 +66%
USAA
48
United Services Automobile Association
Texas
$31.7M -$130K -1,720 -0.4%
Millennium Management
49
Millennium Management
New York
$31.6M -$1.72M -22,688 -5%
Point72 Asset Management
50
Point72 Asset Management
Connecticut
$30M -$77.3M -1,022,323 -73%

AZN Hedge Fund Activity: Q3 2018 in Review

544 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q3 2018, worth a combined $17.3B — up 23% from $14B a quarter earlier.

Buyers outnumbered sellers: 65 funds opened new AZN positions and 47 closed out — a net gain of 18 holders — while 151 added to existing stakes and 197 trimmed.

The largest buyer was Jennison Associates, adding an estimated $774M. The largest seller was Bank of America, cutting an estimated $123M.

  • 544 institutional investors held AstraZeneca (AZN) as of Q3 2018, up from 530 in Q2 2018.
  • Funds reported $17.3B of AstraZeneca stock for Q3 2018, up 23% quarter-over-quarter.
  • 65 funds opened new AstraZeneca positions in Q3 2018 and 47 closed out, a net change of +18 holders.
  • The largest AstraZeneca buyer in Q3 2018 was Jennison Associates, an estimated $774M added.
  • The largest AstraZeneca seller in Q3 2018 was Bank of America, an estimated $123M sold.

Based on aggregated 13F filings for Q3 2018.